September 2, 2024
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
August 13, 2024
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 5, 2024
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
June 4, 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
May 13, 2024
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 10, 2024
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
May 3, 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 12, 2024
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
April 5, 2024
Praxis Precision Medicines to Participate in Upcoming April Conferences
Displaying 11 - 20 of 32